Topical 0.05% cyclosporine a eyedrops for treating moderate-to-severe vernal keratoconjunctivitis

ABSTRACT

This study aimed to investigate the efficacy of topical cyclosporine A [CsA] 0.05% in patients with moderate-to-severe vernal keratoconjunctivitis [VKC]. This retrospective study included 37 patients who were admitted to the clinic between January 2015 and December 2015. All patients were diagnosed with moderate-to-severe VKC and treated with topical CsA 0.05% [Restasis Allergan, Inc. CA, USA]. The VKC diagnosis was based on patient history and typical clinical signs and symptoms. Sign and symptom scores of each patient were obtained at pretreatment and during treatment [1, 3, and 6 months]. Of the 37 patients, 20 [54.1%] were male and 17 [45.9%] were female. The mean age of the patients was 11.83 +/- 4.70 years [6-24 years]. The symptom-sign and total scores of the patients were significantly reduced at 1, 3, and 6 months compared with baseline values. Symptom-sign scores also significantly reduced from 1 month to 3 months and from 3 months to 6 months [P < 0.05]. Topical CsA 0.05% is an effective formulation used for treating moderate-to-severe VKC. It may reduce the need for steroids